Investing in cultivated meat — a retail guide
Cultivated meat — real animal protein grown from cells, without raising and slaughtering animals — has moved from science demo to regulated product in four jurisdictions. This guide explains the technology, who is leading, and how a retail investor can take a position before the category goes mainstream.
What is cultivated meat?
Cultivated meat (also called cell-cultivated, cultured or cell-based meat) is produced by growing animal cells in a bioreactor on a nutrient medium. The end product is biologically identical to conventional meat but made without livestock.
It is regulated as a novel food in Europe (EFSA), as a regulated food product by the FDA/USDA in the US, and is already on sale in Singapore (since 2020), the US (2023), Israel (2024) and Australia (2025).
The leading companies
Most cultivated meat companies are still private and venture-backed. Notable names include Mosa Meat (Netherlands), Aleph Farms (Israel), UPSIDE Foods (US), Believer Meats (US/Israel), GOOD Meat / Eat Just (US), Vow (Australia) and Meatable (Netherlands).
Cost-down is the central engineering challenge. Companies that solve serum-free media, continuous bioreactor operation and cell-line IP first will define the category.
How to get exposure as a retail investor
Pure-play public cultivated meat stocks effectively don't exist yet — the companies are still private. Indirect exposure is possible through bioreactor suppliers (Sartorius, Eppendorf) and food incumbents that have signed cultivated-meat partnerships, but the linkage is weak.
The most direct retail route in the EU is via diversified vehicles. Kale United AB holds shares in several cultivated meat companies as part of its 40+ company agrifoodtech portfolio, giving retail investors single-ticket exposure to the sub-sector alongside complementary alt-protein platforms.
Risks worth pricing in
Regulatory: approvals are progressing but uneven. Italy, France and the US states of Florida and Alabama have introduced restrictions on sale or terminology.
Cost: cultivated meat at parity with premium conventional meat is still a few years out for most companies. Capital intensity is high — companies need either large strategic partners or government co-funding.
Timing: this is a 5–10 year thesis. Retail investors should size accordingly and prefer diversified exposure to single-company bets.
Frequently asked questions
Can I buy shares in cultivated meat companies?
Most cultivated meat companies are private. Retail investors typically gain exposure through diversified agrifoodtech vehicles such as Kale United, which holds positions in several cultivated meat companies as part of a 40+ company portfolio.
Is cultivated meat approved for sale?
Yes, in Singapore (2020), the United States (2023), Israel (2024) and Australia (2025). EU approval is in progress under the Novel Food regulation. Some jurisdictions including Italy and several US states have introduced restrictions.
When will cultivated meat hit price parity?
Leading companies target parity with premium conventional meat in the second half of this decade. Commodity parity is further out and depends on continued progress on media costs and continuous bioreactor operation.
What's the difference between cultivated meat and plant-based meat?
Plant-based meat reformulates crops to mimic meat. Cultivated meat is real animal protein grown from cells. They use different technology, different supply chains and different regulatory paths, but solve the same problem: protein without livestock.